Table 2.
Regimens of therapy
| Treatment | No. (%) | |
|---|---|---|
| HAIC regimen | ||
| FOLFOX | 20 (69) | |
| RALOX | 9 (31) | |
| HTP group | ||
| Lenvatinib + Camrelizumab | 13(44.8) | |
| Lenvatinib + stintilimab | 5(17.2) | |
| Lenvatinib + tislelizumab | 3(10.3) | |
| sorafenib + camrelizumab | 5(17.2) | |
| donafenib + camrelizumab | 3(10.3) | |
| TTP group | ||
| Lenvatinib + Camrelizumab | 13(65.0) | |
| Lenvatinib + stintilimab | 1(5.0) | |
| Lenvatinib + tislelizumab | 1(5.0) | |
| sorafenib + camrelizumab | 2(10.0) | |
| donafenib + camrelizumab | 3(15.0) | |
| HAIC treatment cycle | ||
| Median (range) | 2(1–6) | |
| TACE treatment cycle | ||
| Median (range) | 1(1–3) |
HAIC hepatic arterial infusion chemotherapy, FOLFOX HAIC with oxaliplatin, 5-fluorouracil, and leucovorin, RALOX HAIC with raltitrexed plus oxaliplatin, HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TACE transarterial chemoembolization